The Pharmaceutical Market: Egypt

Date: January 31, 2013
Pages: 111
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PD771A1F61AEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Egypt
OVERVIEW OF THE PHARMACEUTICAL MARKET IN EGYPT

As anticipated by BMI, Egyptian President Mohammad Morsi's relative success in his first100days in officehighlights a degree of political and economic stability,which we believehas resulted in a final resolution of the medicines pricing system. We highlight that our expectation of the government imposing pharmaceutical price caps and adopting a controlled, low-pricing strategy has played out. The new pricing systemsets theprices of medicines higher than the old cost-plus system and BMImaintains this will be good for multinational companies in the mediumterm. However, the dangers of a possible downward pricing spiral, due to the interdependence of countries in the reference pricing basket, is along-term risk to multinationals'revenues.

Headline Expenditure Projections

Pharmaceuticals: EGP18.23bn (US$3.07bn) in 2011 to EGP20.41bn (US$3.37bn) in 2012; +12.0% in local currency terms and +10.0% in US dollar terms. Forecast broadly in line with Q4 12.

Healthcare: EGP62.22bn (US$10.47bn) in 2011 to EGP69.74bn (US$11.53bn) in 2012; +12.1% in local currency terms and +10.1% in US dollar terms. Forecast broadly in line with Q4 12.

Medical devices: EGP3.20bn (US$538mn) in 2011 to EGP3.65bn (US$603mn) in 2012; +14.0% in local currency terms and +12.0% in US dollar terms. Forecast broadly in line with Q4 12.

Risk/Reward Rating: In our latest Pharmaceutical Risk/Reward Ratings (RRRs) for the Middle East and Africa (MEA), Egypt again ranks 11th out of the 30 regional markets surveyed. Egypt's risks score remains below the regional average, in contrast to its more favourable rewards component. Globally, Egypt remains 56th out of 95 markets, between Kazakhstan above it and Morocco below.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

      Egypt Pharmaceuticals & Healthcare Industry SWOT
      Egypt Political SWOT
      Egypt Economic SWOT
      Egypt Business Environment SWOT

PHARMACEUTICALS RISK/REWARD RATINGS

      Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113

EGYPT – MARKET SUMMARY

REGULATORY REGIME

  Lacking Drug Registration Transparency
  Regulatory Developments
  Intellectual Property Developments
  IP Shortcomings
  Counterfeit Medicines
  Free Trade Agreements
  Pricing Regime
  Reimbursement Regime
      Table: Essential Drugs List

INDUSTRY DEVELOPMENTS

  Epidemiology
      Communicable Diseases
      Healthcare Sector
      Private Healthcare Sector
      Healthcare Staff
  Healthcare Financing
  Healthcare Insurance
      Table: Beneficiaries from Health Insurance System, 1999-2008
  Research & Development
  Clinical Trials
  Medical Devices

INDUSTRY FORECAST SCENARIO

  Overall Market Forecast
      Table: Pharmaceutical Sales, 2008-2016
  Healthcare Market Forecast
      Table: Overall Healthcare Expenditure, 2008-2016
      Table: Government Healthcare Expenditure, 2008-2016
      Table: Private Healthcare Expenditure, 2008-2016
  Key Growth Factors – Macroeconomic
  Prescription Drug Market Forecast
      Table: Prescription Drug Sales, 2008-2016
  Patented Drug Market Forecast
      Table: Patented Drug Sales, 2008-2016
  Generic Drug Market Forecast
      Table: Generic Drug Sales, 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales, 2008-2016
  Pharmaceuticals Trade Forecast
      Table: Pharmaceutical Trade, 2008-2016
  Medical Device Market Forecast
      Table: Medical Device Sales, 2008-2016
      Other Healthcare Data
      Key Risks To BMI’s Forecasts

COMPETITIVE LANDSCAPE

  Pharmaceutical Industry
      Table: HOLDIPHARMA’s Affiliated Companies, 2012
      Table: HOLDIPHARMA’s Joint Ventures, 2012
  Domestic Pharmaceuticals Sector
      Table: HOLDIPHARMA’s Financial Indicators, FY 2006/2007-FY2010/2011 (EGPmn)
      Table: HOLDIPHARMA’s Net Operating Revenue by Affiliate, FY 2010/2011 (EGPmn)
      Table: Wholly Or Partially Owned Egyptian Pharmaceutical And Medical Device Companies By Parent Group
  Foreign Pharmaceuticals Sector
  Industry Developments
  Pharmaceutical Wholesale
  Pharmaceutical Retail
  Herbal And OTC Medicine

COMPANY PROFILES

  Domestic Companies
      Egyptian International Pharmaceutical Industries Co (EIPICO)
      South Egyptian Drug Industries (SEDICO)
      Medical Union Pharmaceuticals (MUP)
      Amoun Pharmaceutical Company (APC)
      VASCERA
      Misr Pharmaceuticals
  Multinational Companies
      GlaxoSmithKline (GSK)
      Sanofi
      Pfizer
      Novartis
      Merck & Co
      AstraZeneca

DEMOGRAPHIC OUTLOOK

      Table: Population By Age Group, 1990-2020 (‘000)
      Table: Population By Age Group, 1990-2020 (% of total)
      Table: Key Population Ratios, 1990-2020
      Table: Rural/Urban Population Split, 1990-2020

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceuticals Industry Forecasts
  Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceuticals Business Environment Indicators
      Weighting
      Table: Weighting Of Components
      Sources
Skip to top


Ask Your Question

The Pharmaceutical Market: Egypt
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: